| Category | Summary |
|---|---|
| Identity/Domain | • Human **GATD3** encodes **GATD3A/C21orf33**, matching UniProt **P0DPI2**, a mitochondrial precursor protein with a **class-I glutamine amidotransferase-like (GATase/amidolysis) domain** and evolutionary/structural similarity to **DJ-1/PARK7** (Smith 2022) (pqac-00000004, pqac-00000006, pqac-00000018, pqac-00000019) • Conserved catalytic residues include **E62** and **C176** in GATD3A; cysteine mutagenesis reduces activity (Smith 2022) (pqac-00000000, pqac-00000013, pqac-00000019) |
| Localization | • Experimental fractionation and STED microscopy place GATD3A **primarily in the mitochondrial matrix**, with a smaller **intermembrane-space** pool (Smith 2022) (pqac-00000001, pqac-00000006, pqac-00000007, pqac-00000011, pqac-00000016, pqac-00000018) • Import depends on an **N-terminal mitochondrial targeting signal/MLS** that is cleaved on maturation; protein is largely absent from post-mitochondrial cytosol (Smith 2022) (pqac-00000006, pqac-00000007, pqac-00000011, pqac-00000018) |
| Biochemical activity | • Best-supported primary function is **mitochondrial deglycase activity**: GATD3A removes early non-enzymatic Maillard/glycation adducts generated by reactive **1,2-dicarbonyls** before they mature into AGEs (Smith 2022) (pqac-00000004, pqac-00000006, pqac-00000011, pqac-00000014, pqac-00000015) • Recombinant GATD3A also **hydrolyzes free glutamine** in a luciferase-linked glutamate assay, consistent with an amidolysis-capable GATase fold (Smith 2022) (pqac-00000000, pqac-00000013, pqac-00000019) |
| Substrate specificity | • GATD3A deglycates **DNA/nucleotide and protein/amino-acid adducts** produced by glycation chemistry (Smith 2022) (pqac-00000000, pqac-00000004, pqac-00000013, pqac-00000016) • Available evidence suggests a relative preference for **glyoxal (GO)-derived** modifications, whereas **DJ-1** more strongly handles **methylglyoxal (MGO)-derived** substrates (Smith 2022) (pqac-00000000, pqac-00000002, pqac-00000013, pqac-00000019) |
| Interaction partners | • Co-IP/MS from mitochondria identified partners linked to **mitochondrial mRNA processing/translation**, notably **LRPPRC, SLIRP, TUFM/EFTu** (Smith 2022) (pqac-00000001, pqac-00000002, pqac-00000011, pqac-00000014, pqac-00000016, pqac-00000017) • Additional associations include **ATP5A/ATP5B**, ADP/ATP translocases, chaperones, and respiratory/metabolic proteins, suggesting proximity to inner-membrane bioenergetic machinery (Smith 2022; Ponzone 2024) (pqac-00000002, pqac-00000005, pqac-00000009, pqac-00000014) |
| Pathways/processes | • GATD3A appears to participate in **mitochondrial glycation defense**, acting alongside but distinct from the glutathione-dependent glyoxalase system to restrict **AGE formation** inside mitochondria (Smith 2022) (pqac-00000003, pqac-00000004, pqac-00000006, pqac-00000008, pqac-00000014) • Evidence also links it to **mt-mRNA maturation/translation**, **mitochondrial integrity/dynamics**, and in 2024 work to **TCA-cycle regulation** via the **SIRT3–MDH2** axis in synoviocytes (Smith 2022; Shen 2024) (pqac-00000001, pqac-00000003, pqac-00000011, pqac-00000016, pqac-00000020) |
| Loss/overexpression phenotypes | • **Gatd3a−/−** mice/MEFs show increased mitochondrial **AGE/1,2-dicarbonyl** accumulation on rRNA and proteins, reduced mitochondrial electron density/cristae integrity, and impaired respiration; GO/MGO stress worsens phenotypes (Smith 2022) (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000010, pqac-00000014, pqac-00000016) • **Overexpression** in HEK293 cells/MEFs causes mitochondrial fragmentation and reduced mitochondrial content, implying dosage-sensitive effects on dynamics (Smith 2022) (pqac-00000003, pqac-00000005, pqac-00000008, pqac-00000010) |
| 2023-2024 developments | • **Melanoma proteomics**: GATD3 is significantly upregulated in **RICTOR-deficient BRAF\^V600E** melanoma cells, linking it to adaptive mitochondrial/stress metabolism (Ponzone 2024) (pqac-00000009) • **Osteoarthritis**: GATD3A deficiency promotes fibroblast-like synoviocyte senescence through enhanced **SIRT3–MDH2** interaction, reduced MDH2 activity, impaired TCA flux, and mitochondrial dysfunction; **rAAV-GATD3A** ameliorates OA in mice (Shen 2024) (pqac-00000020, pqac-00000021) • **Wet AMD serum RNA-seq**: circulating GATD3A mRNA is lower in anti-VEGF-treated patients, suggesting biomarker potential but requiring validation (Liukkonen 2024) (pqac-00000022, pqac-00000023, pqac-00000024) |
| Quantitative data points | • Deglycase/amidolysis assays were reported with **n = 3** replicates; GATD3A and DJ-1 reduced AGE formation vs no-enzyme controls, with significance noted at **p < 0.01** (Smith 2022) (pqac-00000000, pqac-00000013) • Co-IP/MS recovered GATD3A with **24 peptides / 351 PSMs**; translation-associated interactors included **LRPPRC 33 peptides / 79 PSMs** and **TUFM 14 peptides / 36 PSMs** (Smith 2022) (pqac-00000005, pqac-00000017) • Knockout MEFs showed reduced OCR; TEM electron-density loss reached **p < 0.001**; overexpression morphology analyses used **N = 21** cells/condition; MGO challenge was **0.2 mM for 24 h** (Smith 2022) (pqac-00000002, pqac-00000005, pqac-00000010) • In melanoma, GATD3 fold-change was **1.55** with **p = 0.0028** (**n = 5**) (Ponzone 2024) (pqac-00000009) • In wAMD serum, treatment-naïve vs anti-VEGF-treated GATD3A counts showed medians **0.03 [0.00–29.59] vs 0.00 [0.00–0.20] CPM**, **P = 0.050**; detectable by qPCR in **44%** of samples (Liukkonen 2024) (pqac-00000022) |
| Applications/real-world | • Current practical use is mainly as a **research target/functional annotation node** for mitochondrial glycation defense, translation-linked quality control, and redox/aging biology (Smith 2022; Shen 2024) (pqac-00000003, pqac-00000008, pqac-00000020) • Emerging translational directions include **gene restoration in OA** (intra-articular **rAAV-GATD3A**) and exploratory **circulating biomarker** studies in AMD; neither is yet established clinically (Shen 2024; Liukkonen 2024) (pqac-00000020, pqac-00000022, pqac-00000023, pqac-00000024) • Proteomic changes in cancer and stress-response studies suggest possible value as a **mitochondrial state marker**, but not yet a validated drug target or diagnostic assay (Ponzone 2024; Liukkonen 2024) (pqac-00000009, pqac-00000023, pqac-00000024) |


*Table: This table summarizes the current functional annotation of human GATD3/GATD3A/C21orf33, emphasizing experimentally supported localization, enzymatic activity, interaction partners, phenotypes, and recent 2024 disease-related findings. It is useful as a compact evidence map for interpreting this still sparsely characterized mitochondrial protein.*